drugset
drugset / Trial / NCT03504488

CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

NCT03504488 ↗

Phase 1/2 Completed 132 enrolled BioAtla, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

The objective of this study is to assess safety and efficacy of CAB-ROR2-ADC in solid tumors

Timeline

Start
2018-06-27
Primary completion
2024-12-30
Completion
2024-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Ozuriftamab Vedotin Unknown — —

Indications

head and neck cancer melanoma non-small cell lung carcinoma triple-negative breast carcinoma